Literature DB >> 17699842

Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?

Wells A Messersmith1, Manuel Hidalgo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699842     DOI: 10.1158/1078-0432.CCR-07-0065

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  19 in total

1.  Epidermal growth factor receptor downregulation by small heterodimeric binding proteins.

Authors:  Benjamin J Hackel; Jason R Neil; Forest M White; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2011-12-09       Impact factor: 1.650

Review 2.  One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.

Authors:  Hyunbo Shim
Journal:  Exp Mol Med       Date:  2011-10-31       Impact factor: 8.718

3.  Design, Synthesis, and Biological Evaluation of Polyaminocarboxylate Ligand-Based Theranostic Conjugates for Antibody-Targeted Cancer Therapy and Near-Infrared Optical Imaging.

Authors:  Siyuan Ren; Xiang Sun; Haixing Wang; Trung Hai Nguyen; Negar Sadeghipour; Xiaochun Xu; Chi Soo Kang; Yujie Liu; Hua Xu; Ningjie Wu; Yanda Chen; Kenneth Tichauer; David D L Minh; Hyun-Soon Chong
Journal:  ChemMedChem       Date:  2018-11-26       Impact factor: 3.466

4.  Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma.

Authors:  Tapan K Nayak; Kayhan Garmestani; Kwamena E Baidoo; Diane E Milenic; Martin W Brechbiel
Journal:  J Nucl Med       Date:  2010-05-19       Impact factor: 10.057

5.  Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.

Authors:  Ben-Fillippo Krippendorff; Diego A Oyarzún; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-03-08       Impact factor: 2.745

6.  A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).

Authors:  José María Viéitez; Manuel Valladares; Ignacio Peláez; Luis de Sande González; Jesús García-Foncillas; José Luis García-López; Carlos García-Girón; Margarita Reboredo; Humberto Bovio; Angel Jiménez Lacave
Journal:  Invest New Drugs       Date:  2010-03-06       Impact factor: 3.850

Review 7.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

Review 8.  Systemic treatment of colorectal cancer.

Authors:  Brian M Wolpin; Robert J Mayer
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

9.  Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent.

Authors:  G L Ray; K E Baidoo; K J Wong; M Williams; K Garmestani; M W Brechbiel; D E Milenic
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

10.  Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma.

Authors:  Chen Huang; Lijun Chen; Sara R Savage; Rodrigo Vargas Eguez; Yongchao Dou; Yize Li; Felipe da Veiga Leprevost; Eric J Jaehnig; Jonathan T Lei; Bo Wen; Michael Schnaubelt; Karsten Krug; Xiaoyu Song; Marcin Cieślik; Hui-Yin Chang; Matthew A Wyczalkowski; Kai Li; Antonio Colaprico; Qing Kay Li; David J Clark; Yingwei Hu; Liwei Cao; Jianbo Pan; Yuefan Wang; Kyung-Cho Cho; Zhiao Shi; Yuxing Liao; Wen Jiang; Meenakshi Anurag; Jiayi Ji; Seungyeul Yoo; Daniel Cui Zhou; Wen-Wei Liang; Michael Wendl; Pankaj Vats; Steven A Carr; D R Mani; Zhen Zhang; Jiang Qian; Xi S Chen; Alexander R Pico; Pei Wang; Arul M Chinnaiyan; Karen A Ketchum; Christopher R Kinsinger; Ana I Robles; Eunkyung An; Tara Hiltke; Mehdi Mesri; Mathangi Thiagarajan; Alissa M Weaver; Andrew G Sikora; Jan Lubiński; Małgorzata Wierzbicka; Maciej Wiznerowicz; Shankha Satpathy; Michael A Gillette; George Miles; Matthew J Ellis; Gilbert S Omenn; Henry Rodriguez; Emily S Boja; Saravana M Dhanasekaran; Li Ding; Alexey I Nesvizhskii; Adel K El-Naggar; Daniel W Chan; Hui Zhang; Bing Zhang
Journal:  Cancer Cell       Date:  2021-01-07       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.